Werewolf Therapeutics raises $120m for IPO

Werewolf Therapeutics, a biopharmaceutical company focused on treating cancer, has raised $120 million for its IPO after pricing its 7.5 million shares at $16 per share.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this